castrate-resistant prostate cancer (crpc). disease progression despite androgen depletion therapy...
TRANSCRIPT
Castrate-resistant prostate cancer (CRPC)
Castrate-resistant prostate cancer (CRPC)
disease progression despite androgen depletion therapy (ADT)
present as :1. continuous rise in PSA2. progression of pre-existing
disease3. appearance of new metastases
"Castrate resistant"
growing despite the hormone therapy with testosterone at "castrate" levels.
Still helped by other forms of hormone therapy
"hormone refractory"
no response to any type of hormone therapy, including the newer medicines.
Combined androgen blockade (CAB)
orchiectomy LHRH agonist + anti-androgenLHRH antagonist
Superior tomonotherapy
CRPC mechanism
Management of CRPC
Secondary hormonal manipulations
In relatively asymptomatic CRPC:
Fir
st
Lin
e
Monotherapy treated (LHRH agonist or orchidectomy):
Total androgen blockade (TAB) with testosterone antagonists, such as bicalutamide , …
( PSA responses in 30% to 35% )Fir
st
Lin
e
TAB patients
First discontinue the antiandrogen : exclude an antiandrogen withdrawal response (AAWD).
Not response?Second line hormonetherapy
(adrenal)
Fir
st
Lin
e
ketoconazoleweak inhibitor of CYP11A and CYP17A
suppresses the synthesis of adrenal and tumor tissue androgens.
nausea and hepatotoxicity
must be given with replacement steroids
PSA response rates around 50%.
Fir
st
Lin
e
First-line systemic chemotherapy In CRPC with detectable
macroscopic metastatic disease
improve survival for CRPC
1996, mitoxantrone was the first chemotherapy
secon
d
Lin
e
Mitoxantronea semi-synthetic anthracycline
first chemotherapy to be approved by (FDA)
no survival benefit in two phase 3 trials
significant improvements of pain
secon
d
Lin
e
late 1990 s, the microtubulestabilizing taxane agents showed promise
secon
d
Lin
e
Docetaxela taxane drug : polymerization of
microtubules and phosphorylation of bcl-2 protein
docetaxel 75 mg/m2 intravenously every 3 weeks + 5 mg oral prednisone twice daily
the standard of care for men with CRPC with detectable metastatic disease.
secon
d
Lin
e
Improve overall survival, disease control, symptom palliation and quality of life
27% increase in progression-free survival (PFS), a 55% increase in objective response rate (ORR), and 1.9-mo improvement in median overall survival (OS)
secon
d
Lin
e
approved by FDA in 2004 and EMA in 2005
Side effect: myelosuppression, fatigue, edema, neurotoxicity, hyperlacrimation, and changes in liver function.s
econ
d
Lin
e
Second-line systemic chemotherapy
docetaxel (again): for no definitive evidence of resistance to docetaxel
Cabazitaxel
Th
ird
Lin
e
Cabazitaxeltubulin-binding taxane
most common serious adverse events :hematological, including grade ≥3 neutropenia in 82% of patients, 8% febrile neutropenia and 5% deaths
prophylactic neutrophil growth factor support :older individuals and with significant prior radiotherapy
Th
ird
Lin
e
Abirateroneoral selective irreversible inhibitor of
the microsomal enzyme cytochrome P17 (17,20-lyase and 17α-hydroxylase)
expected increases in mineralocorticoids upstream of CYP17A
side effects: hypertension, hypokalemia, edema and fatigue treat with low dose glucocorticoids.
Th
ird
Lin
e
The mechanism of action similar to ketoconazole
marked palliative and skeletal related benefits.
FDA approved for treatment
Th
ird
Lin
e
Sipuleucel-TImmunotherapy, FDA-approved agent
vaccine derived from CD54+ dendritic cells, (major antigen-presenting cells)
less than 10% exhibit a clinical, serologic or radiographic response
benefit patients with a lower disease burden and better performance status
Th
ird
Lin
e
All three have an FDA indication in mCRPC
Docetaxel and sipuleucel-T immunotherapy: survival advantage
Abiraterone + prednisone: radiographic progression-free survival benefits
Th
ird
Lin
e
AUA Guideline